The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
P2X7 receptor‐stimulation causes fever via PGE2 and IL‐1β release
Open accessAbstract
Prostaglandins (PGs) are important lipid mediators involved in the development of inflammatory associated pain and fever. PGE2 is a well‐established endogenous pyrogen activated by proinflammatory cytokine interleukin (IL)‐1β. P2X7 receptors (P2X7Rs) expressed by inflammatory cells are stimulated by the danger signal extracellular ATP to activate the inflammasome and release IL‐1β. Here we show that P2X7R activation is required for the release of PGE2 and other autacoids independent of inflammasome activation, with an ATP EC 50 for PGE2 and IL‐1β release of 1.58 and 1.23 mM, respectively. Furthermore, lack of P2X7R or specific antagonism of P2X7R decreased the febrile response in mice triggered after intraperitoneal LPS or IL‐1β inoculation. Accordingly, LPS inoculation caused intraperitoneal ATP accumulation. Therefore, P2X7R antagonists emerge as novel therapeutics for the treatment for acute inflammation, pain and fever, with wider anti‐inflammatory activity than currently used cyclooxygenase inhibitors.—Barberà‐Cremades, M., Baroja‐Mazo, A., Gomez, A. I., Machado, F., Di Virgilio, F., Pelegrín, P. P2X7 receptor‐stimulation causes fever via PGE2 and IL‐1β release. FASEB J. 26, 2951–2962 (2012). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, in a disease state as infection or brain disease, extracellular ATP levels largely increase and activate P2X7 receptors [68–70].”
From Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology (2021) · cites this paper as [70]
In the citing paper
“In fact, the role of P2X7 receptor as a modulator of inflammatory response is well-established [16, 70].”
From Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology (2021) · cites this paper as [70]
Citations
Cites
Molecular Physiology of P2X Receptors
North, R. A. (2002) · Physiological Reviews · doi:10.1152/physrev.00015.2002 · Cited by 2,919
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
The P2X7 Receptor: A Key Player in IL-1 Processing and Release
Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R. M., Curti, A., Idzko, M., Panther, E., & Di Virgilio, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.3877 · Cited by 1,025
Altered Cytokine Production in Mice Lacking P2X7Receptors
Solle, M., Labasi, J. M., Perregaux, D. G., Stam, E. J., Petrushova, N., Koller, B. H., Griffiths, R., & Gabel, C. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006781200 · Cited by 924
Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain
Chessell, I. P., Hatcher, J. P., Bountra, C., Michel, A. D., Hughes, J. P., Green, P., Egerton, J., Murfin, M., Richardson, J. C., Peck, W. L., et al. (2005) · Pain · doi:10.1016/j.pain.2005.01.002 · Cited by 807
Netea, M. G., Nold‐Petry, C. A., Nold, M. F., Joosten, L. A. B., Opitz, B., van der Meer, J. H. M., van de Veerdonk, F. L., Ferwerda, G., Heinhuis, B., Devesa, I., et al. (2008) · Blood · doi:10.1182/blood-2008-03-146720 · Cited by 787
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells
Idzko, M., Hammad, H., van Nimwegen, M., Kool, M., Willart, M. A. M., Muskens, F., Hoogsteden, H. C., Luttmann, W., Ferrari, D., Virgilio, F. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1617 · Cited by 620
Ulmann, L., Hatcher, J. P., Hughes, J. P., Chaumont‐Dubel, S., Green, P. J., Conquet, F., Buell, G. N., Reeve, A. J., Chessell, I. P., & Rassendren, F. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2308-08.2008 · Cited by 572
Pharmacological profiles of cloned mammalian P2Y-receptor subtypes
von Kügelgen, I. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.014 · Cited by 549
Cited by
Sorted by citations
The P2X7 Receptor in Infection and Inflammation
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L., & Falzoni, S. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.020 · Cited by 1,267
Redox Regulation of NLRP3 Inflammasomes: ROS as Trigger or Effector?
Abais, J. M., Xia, M., Zhang, Y., Boini, K. M., & Li, P. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5994 · Cited by 936
Extracellular purines, purinergic receptors and tumor growth
Virgilio, F. D., & Adinolfi, E. (2016) · Oncogene · doi:10.1038/onc.2016.206 · Cited by 567
The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease
Bartlett, R., Stokes, L., & Sluyter, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008003 · Cited by 409
P2X7 receptor: an emerging target in central nervous system diseases
Sperlágh, B., & Illes, P. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.002 · Cited by 390
Metadata
- Authors
- Barberà‐Cremades, M., Baroja‐Mazo, A., Gomez, A. I., Machado, F., Di Virgilio, F., & Pelegrín, P.
- Affiliations
- Inflammation and Experimental Surgery Unit Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas (CIBERhed)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Section of General Pathology, Department of Experimental and Diagnostic Medicine University of Ferrara Ferrara Italy
- ORCID
- Baroja‐Mazo, Alberto
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2012-04-06
- Volume
- 26
- Issue
- 7
- Pages
- 2951-2962
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2147692999
- Cited by
- 142
- References
- 62
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 11 · 2020: 5 · 2019: 18 · 2018: 4 · 2017: 16 · 2016: 13 · 2015: 12 · 2014: 17 · 2013: 11 · 2012: 3
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- P2X7 receptor, fever, prostaglandin E2, IL-1β, extracellular ATP, inflammasome, lipopolysaccharide, endogenous pyrogen, P2X7 receptor antagonists, acute inflammation, inflammatory pain, autacoids
- MeSH terms
- Adenosine Triphosphate, Animals, Fever, Humans, Injections, Intraperitoneal, Leukotriene B4, Lipopolysaccharides, Macrophages, Mice, Inbred C57BL, Recombinant Proteins, Thromboxane B2, Dinoprostone, Mice, Knockout, Inflammation Mediators, Calcium Signaling, MAP Kinase Signaling System, Mice, Cyclooxygenase 2, Interleukin-1beta, Receptors, Purinergic P2X7, Receptors, Purinergic P2X4, Purinergic P2X Receptor Agonists, Purinergic P2X Receptor Antagonists, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
